Characteristics of Otologic Disease Among Patients With Primary Ciliary Dyskinesia.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Goutaki, Myrofora
  • Lam, Yin Ting
  • Alexandru, Mihaela
  • Anagiotos, Andreas
  • Boon, Mieke
  • Burgess, Andrea
  • Caversaccio, Nathalie
  • Crowley, Suzanne
  • Dheyauldeen SAD
  • Emiralioglu, Nagehan
  • Erdem, Ela
  • van Gogh, Christine
  • Gunaydin, Onder
  • Haarman, Eric G.
  • Harris, Amanda
  • Hayn, Isolde
  • Ismail-Koch, Hasnaa
  • Karadag, Bulent
  • Kempeneers, Celine
  • Kim, Sookyung
  • Lorent, Natalie
  • Ozcelik, Ugur
  • Pioch, Charlotte
  • Poirrier AML
  • Roehmel, Jobst
  • Yiallouros, Panayiotis
  • Yumusakhuylu, Ali Cemal
  • Papon, Jean-Francois

Grupos

Abstract

IMPORTANCE: Otologic disease is common among people with primary ciliary dyskinesia (PCD), yet little is known about its spectrum and severity. OBJECTIVE: To characterize otologic disease among participants with PCD using data from the Ear-Nose-Throat Prospective International Cohort. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis of baseline cohort data from February 2020 through July 2022 included participants from 12 specialized centers in 10 countries. Children and adults with PCD diagnoses; routine ear, nose, and throat examinations; and completed symptom questionnaires at the same visit or within 2 weeks were prospectively included. EXPOSURES: Potential risk factors associated with increased risk of ear disease. MAIN OUTCOMES AND MEASURES: The prevalence and characteristics of patient-reported otologic symptoms and findings from otologic examinations, including potential factors associated with increased risk of ear inflammation and hearing impairment. RESULTS: A total of 397 individuals were eligible to participate in this study (median [range] age, 15.2 [0.2-72.4] years; 186 (47%) female). Of the included participants, 204 (51%) reported ear pain, 110 (28%) reported ear discharge, and 183 (46%) reported hearing problems. Adults reported ear pain and hearing problems more frequently when compared with children. Otitis media with effusion-usually bilateral-was the most common otoscopic finding among 121 of 384 (32%) participants. Retracted tympanic membrane and tympanic sclerosis were more commonly seen among adults. Tympanometry was performed for 216 participants and showed pathologic type B results for 114 (53%). Audiometry was performed for 273 participants and showed hearing impairment in at least 1 ear, most commonly mild. Season of visit was the strongest risk factor for problems associated with ear inflammation (autumn vs spring: odds ratio, 2.40; 95% CI, 1.51-3.81) and age 30 years and older for hearing impairment (41-50 years vs =10 years: odds ratio, 3.33; 95% CI, 1.12-9.91). CONCLUSION AND RELEVANCE: In this cross-sectional study, many people with PCD experienced ear problems, yet frequency varied, highlighting disease expression differences and possible clinical phenotypes. Understanding differences in otologic disease expression and progression during lifetime may inform clinical decisions about follow-up and medical care. Multidisciplinary PCD management should be recommended, including regular otologic assessments for all ages, even without specific complaints.

Datos de la publicación

ISSN/ISSNe:
2168-6181, 2168-619X

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY  American Medical Association

Tipo:
Article
Páginas:
587-596
Factor de Impacto:
1,713 SCImago
Cuartil:
Q1 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • OTITIS-MEDIA; CLINICAL-FEATURES; CHILDREN; HEARING; MANIFESTATIONS; EFFUSION; CHOLESTEATOMA; EPIDEMIOLOGY; VENTILATION; DEFECTS

Proyectos asociados

Estudio de mutaciones ocultas en pacientes con sindrome de Usher.

Investigador Principal: JOSÉ MARÍA MILLÁN SALVADOR

2018_0675_CRC_MILLAN . FUNDACION ONCE . 2018

Caracterización clínica y genética de la discinesia ciliar primaria. identificación de nuevos genes y mecanismos moleculares y su traslación al diagnóstico.

Investigador Principal: MIGUEL ARMENGOT CARCELLER

PI19/00949 . INSTITUTO DE SALUD CARLOS III . 2020

ESTUDIO EN FASE IIB, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO, CON GRUPOS PARALELOS Y DE BÚSQUEDA DE DOSIS DE PF-06651600 Y PF-06700841 POR VÍA ORAL COMO TRATAMIENTO DE INDUCCIÓN Y TRATAMIENTO CRÓNICO EN PACIENTES CON COLITIS ULCEROSA MODERADA O GRAVE.

Investigador Principal: MARISA IBORRA COLOMINO

B7981005 . 2017

ESTUDIO DE EXTENSIÓN ABIERTO DE OMALIZUMAB EN PACIENTES CON RINOSINUSITIS CRÓNICA CON PÓLIPOS NASALES.

Investigador Principal: MIGUEL ARMENGOT CARCELLER

WA40169 . 2018

ESTUDIO DE FASE 2B, ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, DE BÚSQUEDA DE DOSIS PARA EVALUAR LA SEGURIDAD Y LA TOLERABILIDAD DE PF-06651600 CON UN PERIODO DE AMPLIACIÓN PARCIALMENTE ENMASCARADO PARA EVALUAR LA SEGURIDAD Y LA TOLERABILIDAD DE PF-06651600 Y PF-06700841 EN PACIENTES ADULTOS CON VITÍLIGO NO SEGMENTARIO ACTIVO.

Investigador Principal: RAFAEL BOTELLA ESTRADA

B7981019 . 2019

UN ESTUDIO EN FASE 2B/3 ALEATORIZADO, CON ENMASCARAMIENTO DOBLE, CONTROLADO CON PLACEBO, DE INTERVALOS DE DOSIS PARA INVESTIGAR LA EFICACIA Y SEGURIDAD DE PF-06651600 EN SUJETOS ADULTOS Y ADOLESCENTES CON ALOPECIA AREATA (AA) CON UNA PÉRDIDA DE CABELLO EN EL CUERO CABELLUDO DEL 50% O MÁS.

Investigador Principal: RAFAEL BOTELLA ESTRADA

B7981015 . 2019

ESTUDIO RETROSPECTIVO DEL EFECTO DE OMALIZUMAB EN LA POLIPOSIS NASAL RECALCITRANTE.

Investigador Principal: MIGUEL ARMENGOT CARCELLER

MAC-OMA-2018-01 . 2019

New DX243-conjugated nanoparticles as a neuroprotective drug for hearing disorders.

Investigador Principal: JOSÉ MARÍA MILLÁN SALVADOR

AC21_2/00022 . COMISION EUROPEA . 2022

Estudio de fase III, aleatorizado, doble ciego, de grupos paralelos para evaluar la eficacia y seguridad de la administración subcutánea de depemokimab 100 mg en pacientes con rinosinusitis crónica con poliposis nasal (RSCcPN) - ANCHOR-2 (Depemokimab en Rinosinusitis Crónica)

Investigador Principal: MIGUEL ARMENGOT CARCELLER

218079 . 2022

Discinesia Ciliar Primaria: del diagnóstico clásico al diagnóstico de precisión basado en la clínica, la imagen y la genómica para un tratamiento individualizado.

Investigador Principal: TERESA JAIJO SANCHÍS

PI22/01010 . INSTITUTO DE SALUD CARLOS III . 2023

Estudio sobre la eficacia del implante de conducción ósea activo transcutáneo BCI 602 en la población pediátrica.

Investigador Principal: LAURA CAVALLE GARRIDO

BCI PEDIÁTRICO . PROPIO GRUPO . 2023

Genetic Screening In Childhood Haering Loss.

Investigador Principal: LAURA CAVALLE GARRIDO

GEN HL . 2023

Cita

Compartir